Stockscreener 앱 받기
31.15
7.40%
-2.49
시간 외 거래:
29.52
-1.63
-5.23%
전일 마감가:
$33.64
열려 있는:
$35.84
하루 거래량:
1.06M
Relative Volume:
2.53
시가총액:
$864.00M
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-9.2985
EPS:
-3.35
순현금흐름:
$-19.25M
1주 성능:
-7.79%
1개월 성능:
+6.13%
6개월 성능:
+28.03%
1년 성능:
+73.25%
1일 변동 폭
$30.95
$35.84
1주일 범위
$30.95
$35.84
52주 변동 폭
$16.20
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Earnings - GuruFocus.com
Castle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Castle Biosciences' revenue growth leads Canaccord to reaffirm $42 stock PT - Investing.com UK
Castle Biosciences (NASDAQ:CSTL) Reaches New 52-Week High After Earnings Beat - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Given New $39.00 Price Target at Robert W. Baird - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Castle Biosciences reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Castle Biosciences Reports Strong Q3 2024 Growth - TipRanks
Castle Biosciences Inc (CSTL) Reports Q3 2024 Earnings: Revenue Hits $85.8 Million, Net Income at $2.3 Million - GuruFocus.com
Castle Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Castle Biosciences Reports Third Quarter 2024 Results - Business Wire
Harbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? - MSN
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: W - GuruFocus.com
Castle Biosciences (NASDAQ:CSTL) Trading Down 3.8%Here's Why - MarketBeat
Castle Biosciences stock soars to 52-week high of $34.55 By Investing.com - Investing.com Canada
Castle Biosciences stock soars to 52-week high of $34.55 - Investing.com
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients - The Bakersfield Californian
The Analyst Landscape: 4 Takes On Castle Biosciences - Benzinga
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $42.00 - MarketBeat
Why Castle Biosciences decided to build new headquarters in Friendswood - The Business Journals
Castle Biosciences to Participate in Upcoming Investor Conferences - The Bakersfield Californian
Castle Biosciences (CSTL) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Castle Biosciences To Report Q2 Results Next Month - RTTNews
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Lowered by SG Americas Securities LLC - MarketBeat
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? - MSN
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors - Business Wire
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? - MSN
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength? - MSN
CSTLCastle Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Castle Biosciences CEO Derek Maetzold sells stock for $165,463 By Investing.com - Investing.com South Africa
Castle Biosciences CEO Derek Maetzold sells stock for $165,463 - Investing.com India
Castle Biosciences, Inc. (NASDAQ:CSTL) Sees Significant Drop in Short Interest - MarketBeat
Derek J. Maetzold Sells 1,972 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences Inc (CSTL) deserves closer scrutiny - US Post News
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential - Business Wire
Potential Price Increase for Castle Biosciences Inc (CSTL) After Recent Insider Activity - Knox Daily
Castle Biosciences Inc Inc. (CSTL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Castle Biosciences (NASDAQ:CSTL) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%? - Simply Wall St
Castle Biosciences price target raised to $40 from $35 at BTIG - Yahoo Finance
Castle Biosciences (NASDAQ:CSTL) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $40.00 - MarketBeat
Castle Biosciences stock soars to 52-week high of $32.55 - Investing.com India
Castle Biosciences stock soars to 52-week high of $32.55 By Investing.com - Investing.com UK
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 - Business Wire
Castle Biosciences (NASDAQ:CSTL) Shares Up 7.3%What's Next? - MarketBeat
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin - Business Wire
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.48%
0.04%
자본화:
|
볼륨(24시간):